Ansa Biotechnologies · Mar 2026
Ansa named Matthias Arenskötter COO to lead global operations, manufacturing, supply chain, and quality systems.
Next-generation DNA synthesis using enzymes
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Ansa Biotechnologies is a privately held Emeryville-based DNA synthesis company that uses proprietary enzymatic technology to produce custom, sequence-perfect DNA fragments and clonal DNA, including ultra-long constructs up to 50 kb, for life-science research and industrial applications.
Primary product
Custom enzymatic DNA synthesis services (DNA Fragments, Clonal DNA, XL Clonal DNA)
Founded
2018
Headquarters
Emeryville, California, United States
Team size
60-70 employees
Industry
Biotechnology Research
Sub-industry
Enzymatic DNA synthesis / synthetic biology
Offices
6 jobs at Ansa Biotechnologies
Business model
Stage
Series B
Total raised
$183.1M
Latest round
Series B · Oct 2025
Latest amount
$54.4M
Oct 2025 · Cerberus Ventures
Apr 2022 · Northpond Ventures
Oct 2021
Jun 2020 · Horizon Ventures
Jun 2019 · National Science Foundation
Leadership
Chief Executive Officer
Chief Financial Officer and Chief Business Officer
Matthias Arenskötter
Chief Operating Officer
Chief Scientific Officer and co-founder
Chief Technology Officer and co-founder
Dave Bullis
Vice President, Strategic Marketing
Scott Fay
Vice President, Informatics
Evan King
Vice President, Sales
Nick Hurt
Vice President, Legal
John Trust
Vice President, Finance
Founders
Co-founder
Investors
Mission-driven and high-performing, with an emphasis on curiosity, rigor, accountability, and cross-disciplinary teamwork to solve difficult DNA-synthesis problems.
Compensation
Public careers materials describe competitive, experience-based base salaries plus stock options; no public salary bands were found. Benefits include medical, dental, vision, 401(k), holidays, flexible vacation, and parental leave.
Benefits
Pricing
Transparent, length- and complexity-based pricing with published prices for fragments and clonal DNA, plus quote-based pricing for custom orders; guaranteed ship dates are part of the offer.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
22.6K
Traffic estimate as of Jun 2026
Ansa Biotechnologies · Mar 2026
Ansa named Matthias Arenskötter COO to lead global operations, manufacturing, supply chain, and quality systems.
Ansa Biotechnologies · Jan 2026
IDT and Ansa announced a strategic collaboration making Ansa Clonal DNA and XL Clonal DNA available to IDT customers for longer, more complex constructs.
Business Wire · Oct 2025
Launch of 50 kb Clonal DNA, described as the longest sequence-perfect synthetic DNA commercially available, backed by Ansa's on-time guarantee.
Business Wire · Oct 2025
Series B financing closed and committed capital totaled $54.4M, led by Cerberus Ventures, to expand manufacturing and product development.
Business Wire · May 2025
Ansa opened early access orders for complex DNA up to 50 kb, targeting long and complex constructs in research and therapeutic workflows.